Excess risk of bleeding in patients with venous thromboembolism on direct oral anticoagulants during initial and extended treatment versus population controls
Open Access
- 13 February 2025
- journal article
- Published by Wiley in Journal of Internal Medicine
- Vol. 297 (4) , 382-399
Abstract
Background: The risk of major bleeding from anticoagulant treatment is influenced by both the treatment and the patient's baseline risk, which is often disregarded. Objectives: To determine the excess bleeding risk in venous thromboembolism (VTE) cases during initial (0 to 6 months) and extended (6 months to 5 years) treatment compared to matched population controls without VTE or anticoagulant treatment, overall, and stratified by sex and age. Methods: Cancer‐free patients with VTE treated with direct oral anticoagulants from 2014 to 2020, along with propensity score–matched controls, were identified from nationwide Swedish registers. Excess risk of major bleeding was assessed using the incidence rate difference (IRD) calculated by subtracting the control bleeding rate from the case bleeding rate. Results: The matched cohort comprised 36,115 VTE cases and 36,115 controls. During initial treatment, 388 VTE cases (1.07%) and 103 controls (0.29%) experienced bleeding, IRD: 2.19 (95% confidence interval 1.89–2.49) per 100 person‐years. Following rematching at 6 months, 139 cases (0.70%) and 214 controls (1.08%) experienced bleeding, IRD: 0.70 (0.52–0.89). During initial treatment, females had a higher excess bleeding risk than males, with male IRD: 1.73 (1.34–2.12) and female IRD: 2.69 (2.23–3.15). Excess bleeding risk was highest in the oldest patient population. In extended treatment, excess bleeding was not dependent on sex—male IRD: 0.60 (0.35–0.85), female IRD: 0.81 (0.54–1.08)—and did not increase with age. Conclusion: The excess bleeding risk from anticoagulant treatment was high during initial treatment, particularly among females and the elderly, but lower and not influenced by sex or age during extended treatment.Keywords
Funding Information
- Vetenskapsrådet (2023‐02144)
- Vetenskapsrådet (VRREG 2019‐00193)
- Göteborgs Läkaresällskap (GLS‐986108)
- Hjärt-Lungfonden (2021‐0702)
- Hjärt-Lungfonden (2022‐0216)
- Sahlgrenska University Hospitals Research Foundations (SU‐984390)
This publication has 25 references indexed in Scilit:
- Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment—A nationwide register‐based studyJournal of Internal Medicine, 2023
- Incidence and clinical impact of bleeding events in older patients with acute venous thromboembolismBlood Advances, 2023
- Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous ThromboembolismJAMA, 2022
- Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolismAmerican Journal of Health-System Pharmacy, 2020
- Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysisBMJ, 2019
- Real‐life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral AnticoagulantsClinical Pharmacology & Therapeutics, 2017
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2014
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006
- Prediction of the Risk of Bleeding During Anticoagulant Treatment for Venous ThromboembolismArchives of internal medicine (1960), 1999